Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
06.01. | GRI Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
23.12.24 | GRI Bio, Inc.: GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds | 93 | GlobeNewswire (Europe) | - Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI... ► Artikel lesen | |
20.12.24 | GRI Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.12.24 | GRI Bio, Inc.: GRI Bio to Participate in the Virtual Investor Closing Bell Series | 3 | GlobeNewswire (USA) | ||
21.11.24 | GRI Bio reports progress in IPF treatment with GRI-0621 | 1 | Investing.com | ||
21.11.24 | GRI Bio vermeldet Fortschritte bei IPF-Behandlung mit GRI-0621 | - | Investing.com Deutsch | ||
21.11.24 | GRI Bio, Inc.: GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) | 108 | GlobeNewswire (Europe) | Workshop, poster and oral presentation of data given as part of the 8th Annual Antifibrotic Drug Development (AFDD) Summit Data demonstrate that NKT cells are activated in airways in IPF patients... ► Artikel lesen | |
GRI BIO Aktie jetzt für 0€ handeln | |||||
15.11.24 | GRI Bio reports 9M results | 1 | Seeking Alpha | ||
14.11.24 | GRI Bio files to sell 1.58M shares of common stock for holders | 2 | Seeking Alpha | ||
14.11.24 | GRI Bio, Inc.: GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis | 109 | GlobeNewswire (Europe) | $13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study Topline... ► Artikel lesen | |
14.11.24 | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
24.10.24 | GRI Bio sichert Finanzierung zur Weiterentwicklung der IPF-Behandlung bis 2025 | 2 | Investing.com Deutsch | ||
24.10.24 | GRI Bio, Inc.: GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 | 148 | GlobeNewswire (Europe) | Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment... ► Artikel lesen | |
22.10.24 | GRI BIO, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
21.10.24 | GRI Bio, Inc.: GRI Bio Announces Exercise of Warrants | 9 | GlobeNewswire (USA) | ||
16.10.24 | GRI Bio reports progress in IPF treatment study | 3 | Investing.com | ||
16.10.24 | GRI Bio, Inc.: GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) | 3 | GlobeNewswire (USA) | ||
08.10.24 | Ascendiant Capital sets 12-month target on GRI Bio with Buy rating | 2 | Investing.com | ||
08.10.24 | Ascendiant Capital setzt 12-Monats-Kursziel für GRI Bio mit Kaufempfehlung | 2 | Investing.com Deutsch | ||
07.10.24 | GRI Bio, Inc.: GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis | 2 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 110,40 | -0,27 % | BioNTech Aktie: Geplante Maßnahmen und Strategien | Die BioNTech-Aktie zeigt sich in den ersten Januarwochen 2025 weitgehend stabil. Am Handelstag des 18. Januar verzeichnete das Papier einen leichten Rückgang von 0,74 Prozent auf 111,93 USD. Die Marktkapitalisierung... ► Artikel lesen | |
EVOTEC | 7,975 | -0,31 % | Bechtle, CompuGroup, Continental, Evotec, SMA Solar, Varta u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
CUREVAC | 3,838 | +0,05 % | CureVac Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
AMGEN | 262,50 | -0,10 % | Amgen Aktie: Starkes Wachstum sichert Zukunft | Die Amgen Aktie zeigt sich zum Jahresstart 2025 in robuster Verfassung. Der Biotechnologie-Konzern verzeichnete am 18. Januar einen Kursanstieg von 0,99% auf 272,11 USD. Besonders bemerkenswert ist... ► Artikel lesen | |
CORE ONE LABS | 0,079 | -100,00 % | Prusa gibt Update zum 3D-Drucker CORE One: Erste Auslieferungen stehen bevor | ||
DEFENCE THERAPEUTICS | 0,570 | +5,17 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,408 | +3,03 % | PTA-News: Small- & MicroCap Investment: Merck hat es vorgemacht: NurExone sichert sich Master Cell Bank | DJ PTA-News: Small- & MicroCap Investment: Merck hat es vorgemacht: NurExone sichert sich Master Cell Bank
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt (pta/19.01.2025/08:00) - Anfang... ► Artikel lesen | |
IBIO | 3,050 | 0,00 % | iBio, Inc.: iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio | SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development... ► Artikel lesen | |
ARROWHEAD PHARMACEUTICALS | 19,385 | +2,38 % | AKTIONÄR-Favorit Arrowhead Pharmaceuticals: Wichtiger Meilenstein | Gute Nachrichten von Arrowhead Pharmaceuticals am Freitagabend. Die US-Gesundheitsbehörde FDA hat den Antrag auf Marktzulassung des Unternehmens für Plozasiran zur Behandlung von Patienten mit einer... ► Artikel lesen | |
COHERUS | 1,283 | +1,58 % | Coherus BioSciences, Inc.: Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | - Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate - - Antitumor... ► Artikel lesen | |
CHIMERIX | 3,630 | +0,14 % | Chimerix-Aktie erreicht 52-Wochen-Hoch bei 3,8 US-Dollar | ||
VOYAGER THERAPEUTICS | 5,300 | +1,44 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2024 Financial and Operating Results | - Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data... ► Artikel lesen | |
OPGEN | 0,438 | +7,35 % | OPGEN INC - 8-K, Current Report | ||
MEREO BIOPHARMA | 2,880 | +2,86 % | Mereo BioPharma Group plc: Mereo BioPharma Provides Update on Lead Clinical Programs | Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease... ► Artikel lesen | |
BENITEC BIOPHARMA | 10,560 | 0,00 % | Benitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update | -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical... ► Artikel lesen |